MedTrace Logo

64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer

NCT01939275 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-02-28

Study results available
· View outcomes & findings →

Summary

This pilot clinical trial studies copper Cu 64 (64Cu) tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab positron emission tomography (PET)/computed tomography (CT) in studying patients with gastric, or stomach cancer. Diagnostic procedures, such as copper Cu 64-DOTA-trastuzumab PET/CT, may help doctors study the characteristics of tumors and choose the best treatment.

Conditions

  • Adenocarcinoma of the Gastroesophageal Junction
  • Diffuse Adenocarcinoma of the Stomach
  • Intestinal Adenocarcinoma of the Stomach
  • Mixed Adenocarcinoma of the Stomach
  • Recurrent Gastric Cancer
  • Stage IA Gastric Cancer
  • Stage IB Gastric Cancer
  • Stage IIA Gastric Cancer
  • Stage IIB Gastric Cancer
  • Stage IIIA Gastric Cancer
  • Stage IIIB Gastric Cancer
  • Stage IIIC Gastric Cancer
  • Stage IV Gastric Cancer

Interventions

RADIATION

copper Cu 64-DOTA-trastuzumab

Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan

DEVICE

positron emission tomography

Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan

OTHER

laboratory biomarker analysis

Correlative studies

PROCEDURE

Computed Tomography

Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan

Sponsors & Collaborators

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Yanghee Woo, MD · City of Hope Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-19
Primary Completion
2019-03-30
Completion
2024-08-05

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01939275 on ClinicalTrials.gov